Enzo Biochem Inc. (NYSE: ENZ) announced today an expanded business arrangement between its wholly owned subsidiary, Enzo Life Sciences, and Tokyo-based Cosmo Bio Co., Ltd. (JASDAQ: 3386). Under the terms of the arrangement, Cosmo Bio—a distributor of Enzo Life Sciences products in Japan for over 20 years—will assume a leadership position in Japan in the promotion, sales, and high level technical and customer support for Enzo Life Sciences products. In addition, Enzo will make Cosmo Bio’s extensive catalog of Japanese manufactured research biotools, for which it is a leading distributor, available to researchers around the world through Enzo’s extensive global distribution network. This arrangement materially widens the span of biosciences products offered by both companies and increases the accessibility of the collective portfolio to customers worldwide. “Cosmo Bio is a leading distributor of research products and custom services to Japan’s academic, pharmaceutical and biotech communities, and expansion of our relationship with Cosmo Bio will provide Japan’s researchers with improved access to a broader range of Enzo products backed by extensive and efficient technical and sales support,” said Barry Weiner, President of Enzo Biochem. Dr. Haruhisa Sakurai, a company Director at Cosmo Bio Co., Ltd. commented that "we are proud to strengthen our relationship with Enzo Life Sciences. Cosmo Bio and Enzo share similar company core values in their dedication to supplying quality products and delivering outstanding customer service to the world marketplace. Our expanded alliance with Enzo and the introduction of thousands of Japanese manufactured biotools to be offered by Cosmo Bio’s export division through Enzo Life Sciences’s worldwide distribution system further expands the choices and opportunities available to our customers worldwide.” About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and rapidly deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
About Cosmo Bio Co., Ltd.Tokyo-based Cosmo Bio Co., Ltd. is one of Japan’s largest direct importers of reagent-based products and small instruments for life science research. For over 25 years, Cosmo Bio has been a focal point for researchers seeking the most up-to-date products and product information available from hundreds of manufacturers around the world. With its extensive inventory and efficient logistics, Cosmo Bio provides Japan’s researchers with rapid access to these products through its network of approximately 200 local subdealers throughout Japan. In addition, Cosmo Bio’s export division provides life science researchers outside Japan easy access to thousands of Japan-made research biotools and small instruments, both directly and through its USA subsidiary, Cosmo Bio USA, located in Carlsbad, CA. Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2011. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.